JP2013520466A - 二量体iap阻害剤 - Google Patents

二量体iap阻害剤 Download PDF

Info

Publication number
JP2013520466A
JP2013520466A JP2012554332A JP2012554332A JP2013520466A JP 2013520466 A JP2013520466 A JP 2013520466A JP 2012554332 A JP2012554332 A JP 2012554332A JP 2012554332 A JP2012554332 A JP 2012554332A JP 2013520466 A JP2013520466 A JP 2013520466A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
pyridin
pyrrolidin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012554332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520466A5 (https=
Inventor
クリストファー・ショーン・ストロ−ブ
チェン・ズオリアン
マーク・ジー・パレルモ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013520466A publication Critical patent/JP2013520466A/ja
Publication of JP2013520466A5 publication Critical patent/JP2013520466A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012554332A 2010-02-25 2011-02-23 二量体iap阻害剤 Pending JP2013520466A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US61/308,114 2010-02-25
US33392710P 2010-05-12 2010-05-12
US61/333,927 2010-05-12
US38841010P 2010-09-30 2010-09-30
US61/388,410 2010-09-30
PCT/EP2011/052662 WO2011104266A1 (en) 2010-02-25 2011-02-23 Dimeric iap inhibitors

Publications (2)

Publication Number Publication Date
JP2013520466A true JP2013520466A (ja) 2013-06-06
JP2013520466A5 JP2013520466A5 (https=) 2014-03-20

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554332A Pending JP2013520466A (ja) 2010-02-25 2011-02-23 二量体iap阻害剤

Country Status (13)

Country Link
US (1) US8445440B2 (https=)
EP (1) EP2539333A1 (https=)
JP (1) JP2013520466A (https=)
KR (1) KR20130010894A (https=)
CN (1) CN102834389A (https=)
AR (1) AR080253A1 (https=)
BR (1) BR112012021291A2 (https=)
CA (1) CA2790302A1 (https=)
EA (1) EA201201177A1 (https=)
MX (1) MX2012009894A (https=)
TW (1) TW201141846A (https=)
UY (1) UY33236A (https=)
WO (1) WO2011104266A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US9453048B2 (en) 2012-08-09 2016-09-27 Bristol-Myers Squibb Company IAP antagonists
CA2930030A1 (en) * 2012-11-09 2014-05-15 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Iapbirドメイン結合化合物
JP2009545613A (ja) * 2006-08-02 2009-12-24 ノバルティス アクチエンゲゼルシャフト Iap阻害剤として有用なsmacペプチド模倣物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
KR20090046973A (ko) 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN1953744A (zh) 2004-02-05 2007-04-25 诺瓦提斯公司 Dna拓扑异构酶抑制剂和iap抑制剂的组合
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2617642A1 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Iap-억제제와 탁산의 조합물
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US7807699B2 (en) 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
JP2010511057A (ja) 2006-11-28 2010-04-08 ノバルティス アーゲー 急性骨髄性白血病の処置のためのiap阻害剤の使用
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク. 抗癌剤として有用なsmac模倣二量体及び三量体
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
JP2010528587A (ja) 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
AU2009203971A1 (en) 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of IAP
CA2712604A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
AU2009261919A1 (en) 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック, インコーポレイテッド Iapのインヒビター
US20120009141A1 (en) 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2010033531A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Iapbirドメイン結合化合物
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2009545613A (ja) * 2006-08-02 2009-12-24 ノバルティス アクチエンゲゼルシャフト Iap阻害剤として有用なsmacペプチド模倣物

Also Published As

Publication number Publication date
KR20130010894A (ko) 2013-01-29
CA2790302A1 (en) 2011-09-01
AU2011219862A1 (en) 2012-09-06
EP2539333A1 (en) 2013-01-02
BR112012021291A2 (pt) 2016-10-25
WO2011104266A1 (en) 2011-09-01
MX2012009894A (es) 2012-09-12
TW201141846A (en) 2011-12-01
CN102834389A (zh) 2012-12-19
US8445440B2 (en) 2013-05-21
UY33236A (es) 2011-09-30
EA201201177A1 (ru) 2013-04-30
AR080253A1 (es) 2012-03-21
US20110206690A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
US8445440B2 (en) Dimeric IAP inhibitors
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
US8993523B2 (en) Dimeric IAP inhibitors
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
JP2020535218A (ja) SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
EA030539B1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
US20130266590A1 (en) Dimeric iap inhibitors
CN117642416A (zh) 分拣蛋白活性调节剂
WO2021060453A1 (ja) 架橋型光学活性2級アミン誘導体
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
CN102325768A (zh) 治疗疼痛和其他疾病的化合物和方法
AU2020201109A1 (en) NMDA receptor modulators and prodrugs, salts, and uses thereof
CN103373997B (zh) 含有锌结合基的吡啶并萘啶类HDAC和mTOR抑制剂
AU2011219862B2 (en) Dimeric IAP inhibitors
JP2025506445A (ja) Klf2の誘導物質およびその使用方法
WO2014150252A1 (en) Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP4444728A1 (en) Lonp1 inhibitor compounds, uses and methods
HK40111688A (zh) Klf2诱导剂及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140820

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630